Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Senior Clinical Editor
Senior Director, Educational Strategy
Senior Managing Editor
This program is intended for physicians, nurses, and other healthcare professionals who provide care for patients with bladder cancer.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2018, through April 29, 2019:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
Analysis of phase III IMpower132 trial evaluating the addition of atezolizumab to first-line chemotherapy in NSCLC: PFS, safety, and interim OS.
Results from phase I/III IMpower133 trial evaluating addition of atezolizumab to first-line chemotherapy in extensive-stage SCLC from WCLC 2018 reported by Clinical Care Options (CCO).
Results from PACIFIC trial of durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC from WCLC 2018 reported by Clinical Care Options (CCO).
Interim analysis of the phase III ALTA-1L trial of brigatinib vs crizotinib in ALK inhibitor–naive patients with ALK-positive advanced NSCLC
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.